Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
Portfolio Pulse from Vandana Singh
The high demand for GLP-1 medications like Ozempic and Zepbound for weight loss is causing shortages, leaving type 2 diabetic patients without access to these critical drugs. This surge is driven by social media and off-label use, impacting companies like Novo Nordisk and Eli Lilly.
July 19, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Eli Lilly's Mounjaro and Zepbound are also experiencing shortages due to increased off-label use for weight loss, affecting type 2 diabetic patients' access to these medications.
The increased off-label use of Mounjaro and Zepbound for weight loss is leading to supply shortages, which could negatively impact Eli Lilly's stock as it fails to meet the needs of its diabetic patients.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
NEGATIVE IMPACT
Novo Nordisk's Ozempic is facing significant supply issues due to high off-label demand for weight loss, impacting type 2 diabetic patients' access to the drug.
The high off-label demand for Ozempic for weight loss is causing supply shortages, which could negatively impact Novo Nordisk's stock as it struggles to meet the needs of its primary diabetic patient base.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100